Pacific Biosciences of California, Inc.
Equity & Debt
| Period | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| Mar 2017 | — | $69.2M | $29.0M |
| Jun 2017 | — | $115.9M | $36.5M |
| Sep 2017 | — | $101.4M | $25.9M |
| Dec 2017 | $13.6M | $86.1M | $16.5M |
| Mar 2018 | $13.9M | $102.7M | $25.5M |
| Jun 2018 | $14.1M | $85.5M | $23.1M |
| Sep 2018 | $14.4M | $131.9M | $38.1M |
| Dec 2018 | $14.7M | $114.1M | $18.8M |
| Mar 2019 | $14.9M | $94.9M | $38.2M |
| Jun 2019 | $15.2M | $75.8M | $30.4M |
| Sep 2019 | $15.5M | $51.0M | $33.1M |
| Dec 2019 | $15.9M | $54.9M | $29.6M |
| Mar 2020 | — | $60.4M | $68.9M |
| Jun 2020 | — | $41.4M | $43.3M |
| Sep 2020 | — | $129.5M | $69.0M |
| Dec 2020 | — | $335.5M | $81.6M |
| Mar 2021 | $895.7M | $280.6M | $932.4M |
| Jun 2021 | $895.8M | $258.2M | $459.8M |
| Sep 2021 | $895.9M | $840.8M | $425.4M |
| Dec 2021 | $896.1M | $791.0M | $460.7M |
| Mar 2022 | $896.2M | $734.6M | $428.6M |
| Jun 2022 | $896.4M | $681.9M | $310.4M |
| Sep 2022 | $896.5M | $626.6M | $304.4M |
| Dec 2022 | $896.7M | $562.9M | $325.1M |
| Mar 2023 | $896.8M | $692.1M | $353.8M |
| Jun 2023 | — | $642.0M | $209.3M |
| Sep 2023 | — | $763.7M | $385.6M |
| Dec 2023 | — | $701.3M | $179.9M |
| Mar 2024 | — | $649.0M | $76.6M |
| Jun 2024 | — | $492.7M | $99.5M |
| Sep 2024 | — | $453.1M | $78.0M |
| Dec 2024 | — | $506.6M | $55.4M |
| Mar 2025 | — | $91.6M | $58.5M |
| Jun 2025 | — | $61.5M | $54.8M |
| Sep 2025 | — | $36.1M | $56.5M |
| Dec 2025 | — | $5.3M | $63.7M |
| Mar 2026 | — | $2.4M | $56.3M |
| Jun 2026 | — | $-33.2M | $61.0M |